Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Background Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann–Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
New England Journal of Medicine
2015
|
| Online Access: | http://hdl.handle.net/1721.1/97178 |